| Bid | 1.91 |
| Market Cap | 68.63M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.55 |
| PE Ratio (ttm) | -3.6 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.15 |
| Volume | 46,285 |
| Avg. Volume (20D) | 161,981 |
| Open | 1.91 |
| Previous Close | 1.88 |
| Day's Range | 1.91 - 2.11 |
| 52-Week Range | 1.08 - 46.00 |
| Beta | undefined |
About FBLG
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the tr...
Analyst Forecast
According to 5 analyst ratings, the average rating for FBLG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 506.06% from the latest price.
11 months ago · seekingalpha.com
U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large ListingsSports equipment and apparel maker Amer Sports priced below the range to raise $1.3 billion at a $6.4 billion market cap. CNS disorder biotech Alto Neuroscience priced its upsized IPO at the top of th...
